Cumulative Effects of Aldosterone Synthase and SGLT2 Inhibition on Albuminuria in People with CKD
Peter Rossing(Steno Diabetes Centers), Katherine R. Tuttle(Providence Regional Medical Center Everett), Dick de Zeeuw(University Medical Center Groningen), Shimoli Shah(Boehringer Ingelheim (Germany)), Juliane Meyerhoff(Boehringer Ingelheim (Germany)), Sibylle J. Hauske(Heidelberg University), Lisa Cronin(Boehringer Ingelheim (Germany)), Hiddo Jan L. Heerspink, Zhichao Sun(Boehringer Ingelheim (Japan))
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k